In the clinical study, led by researchers at the Dana Farber Cancer Institute, over half of patients with non-small-cellular lung cancer (NSCLC) having have mutation in the gene HER2, their tumors stopped growing and shrinking for an extended period after a drug was treated that hits a chemotherapy agent in a very precisely focused antibody. https://www.coherentmarketinsights.com/news/antibody-drug-combination-shows-significant-activity-in-her2-gene-mutating-in-individuals-with-non-small-cell-lung-cancer-510